e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Asthma management and response
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Asthma control and lung function after step down from high dose ICS/LABA combination therapy
P. Paggiaro, N. Gabriele, N. Crimi, L. M. Fabbri, D. Olivieri, A. Rossi, A. Papi (Pisa, Parma, Catania, Modena, Verona, Ferrara, Italy)
Source:
Annual Congress 2011 - Asthma management and response
Session:
Asthma management and response
Session type:
Thematic Poster Session
Number:
3967
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Paggiaro, N. Gabriele, N. Crimi, L. M. Fabbri, D. Olivieri, A. Rossi, A. Papi (Pisa, Parma, Catania, Modena, Verona, Ferrara, Italy). Asthma control and lung function after step down from high dose ICS/LABA combination therapy. Eur Respir J 2011; 38: Suppl. 55, 3967
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy
Source: Eur Respir J 2005; 26: Suppl. 49, 382s
Year: 2005
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 49s
Year: 2003
Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept